impedimed ltd (IPD:ASX)
impedimed ltd (IPD) Snapshot
|
Open
A$0.11
|
Previous Close
A$0.10
|
|
|
Day High
A$0.12
|
Day Low
A$0.11
|
|
|
52 Week High
06/21/12 - A$0.30
|
52 Week Low
04/24/13 - A$0.05
|
|
|
Market Cap
20.9M
|
Average Volume 10 Days
197.8K
|
|
|
EPS TTM
A$-0.07
|
Shares Outstanding
181.3M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
impedimed ltd (IPD) Related Businessweek News
No Related Businessweek News Foundimpedimed ltd (IPD) Details
ImpediMed Limited engages in the development, manufacture, and sale of bioimpedance instruments and consumables for clinicians and allied health professionals in Australia, North America, and rest of world. The company offers non-invasive medical devices for use in the subclinical assessment of individuals at risk of secondary lymphoedema; and monitoring of body composition and hydration. It also supplies power precision testing and measuring equipment. The company was founded in 1999 and is based in Pinkenba, Australia.
impedimed ltd (IPD) Top Compensated Officers
impedimed ltd (IPD) Key Developments
ImpediMed Limited announced that director Martin Kriewaldt will retire from the Board effective July 2013 to be replaced by Scott R Ward. Founder and long term chairman Mel Bridges will retire from the board at the 2013 AGM. Scott R. Ward will be appointed to the ImpediMed Board on Mr. Kriewaldt's retirement in July. He was formerly an officer at Medtronic and the Senior Vice President and President of Medtronic CardioVascular. He currently serves on multiple other Boards, including SurModics, Inc, Creganna-Tactx Medical and Gillette Children's Specialty Healthcare.
ImpediMed Limited announced the resignation of Peggy Brooker, COO and CFO. In addition, the U.S. Headquarters has completed the final phase of its strategic realignment, which includes the departure of ImpediMed's Sr. VP of Sales and Marketing, William Gearhart, as well as Sr. VP of Business Development, Jack Butler, and two other professionals. Additionally, Morten Vigeland has been promoted to the position of Vice President of Global Finance.
ImpediMed Limited announced that they will report Q2, 2013 results on Feb 22, 2013
| Recently Viewed | |||
| IPD:AU | A$0.12 AUD | +0.015 |  |
| Company | Last | Change | |
| No competitor information is available for IPD. | |||
| View Industry Companies | |||
Industry Analysis
IPD
Industry Average
| Valuation | IPD | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 6.4x |
|
| Price/Book | 1.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.3x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact IMPEDIMED LTD, please visit www.impedimed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
